<DOC>
	<DOCNO>NCT01340768</DOCNO>
	<brief_summary>This study compare incidence hypoglycemia use sitagliptin treatment versus sulfonylurea ( SU ) treatment participant type 2 diabetes mellitus ( T2DM ) regularly take SU drug , choose fast month Ramadan . The primary hypothesis 30 day Ramadan fasting , treatment sitagliptin ( without metformin ) compare SU treatment ( without metformin ) result low incidence hypoglycemia participant T2DM .</brief_summary>
	<brief_title>Study Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting Patients With Type 2 Diabetes ( MK-0431-262 )</brief_title>
	<detailed_description>This study NCT01131182 ( MK-0431-263 ) design conduct separate protocol , different country , accord local guideline .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Muslim , type 2 diabetes mellitus Intends fast month Ramadan Hemoglobin A1c ( HbA1c ) ≤10 % screen On stable dose SU drug ( glibenclamide , glimepiride , gliclazide ) , least three month , without metformin therapy stable dose Type 1 diabetes mellitus Pregnant breast feed gestational diabetes Hypersensitivity contraindication dipeptidyl peptidase4 ( DPP4 ) treatment Serum creatinine ≥1.5 mg/dL ( male ) , ≥1.4 mg/dL ( female ) History severe hypoglycemia ( defined hypoglycemic event require assistance another individual , and/or result emergency department admission , physician office visit and/or hospitalization ) Any use insulin ( prior Ramadan ) Use class oral antidiabetic therapy SU metformin Current participation another interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Glucose metabolism disorder Metabolic diseases Peptidase inhibitor</keyword>
</DOC>